Description: A Phase 1b Study to Assess the Combination of Selinexor and Daratumumab in Patients with Relapsed / Refractory Multiple Myeloma Previously Exposed to Proteasome Inhibitors (PI) and Immunomodulatory Drugs (IMiDs)
Cristina J. Gasparetto, MD
Duke University Cancer Center,
Durham, NC, USA
Introduction: Selinexor is a first-in-class Selective Inhibitor of Nuclear Export (SINE) compound that binds and inactivates Exportin 1 (XPO1). Selinexor, as a single agent, or in combination with PIs or IMiDs, has shown anti-MM activity in patients (pts) with relapsed or refractory multiple myeloma (RRMM). Daratumumab, an anti-CD38 monoclonal antibody, is approved for the treatment of RRMM. In this study, we aim to explore the safety and efficacy of selinexor in combination with daratumumab and low dose dexamethasone (SDd) in pts with RRMM.
Conclusions: Selinexor 100 mg QW, can be combined safely with daratumumab and dex. The activity observed in the first 3 pts is promising with all 3 pts responding to therapy. Enrollment is ongoing and updated data from 100 mg QW cohort, 100 mg QW expansion, and full phase 1 will be updated and presented.
Authors: Cristina J. Gasparetto, MD, Suzanne Lentzsch, MD, PhD, Gary J Schiller, MD, William Bensinger, MD, Nizar J. Bahlis, MD, Heather J. Sutherland, MD, PhD, FRCPC, Darrell J White, MD, Michael Sebag, MD, PhD, Rami Kotb, MD, Christopher P. Venner, MD, Richard Leblanc, MD, FRCPC, Christine I Chen, MD, Aldo Del Col, BSPharm, MBA, Michael G. Kauffman, MD, PhD, Sharon Shacham, PhD, MBA, Jacqueline Jeha, Jean-Richard Saint-Martin, Jatin Shah, MD and Brea C. Lipe, MD